Registration Strip Icon for monitor Monitora più quotazioni in tempo reale dalle principali borse, come Borsa Italiana, NASDAQ, NYSE, AMEX, Bovespa e altro ancora.

PCVX

Vaxcyte (PCVX)

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:PCVX
DataOraFonteTitoloSimboloCompagnia
10/06/202422:19Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PCVXVaxcyte Inc
10/06/202422:13Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PCVXVaxcyte Inc
03/06/202422:02Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:PCVXVaxcyte Inc
24/05/202423:05Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:PCVXVaxcyte Inc
08/05/202422:10Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PCVXVaxcyte Inc
08/05/202422:05GlobeNewswire Inc.Vaxcyte Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:PCVXVaxcyte Inc
02/04/202422:05GlobeNewswire Inc.Vaxcyte to Present at the 23rd Annual Needham Virtual Healthcare ConferenceNASDAQ:PCVXVaxcyte Inc
04/03/202414:30GlobeNewswire Inc.Vaxcyte Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease (IPD) in InfantsNASDAQ:PCVXVaxcyte Inc
27/02/202422:58Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:PCVXVaxcyte Inc
27/02/202422:01GlobeNewswire Inc.Vaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:PCVXVaxcyte Inc
15/02/202422:05GlobeNewswire Inc.Vaxcyte to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024NASDAQ:PCVXVaxcyte Inc
03/02/202400:39GlobeNewswire Inc.Vaxcyte Announces Closing of $862.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional SharesNASDAQ:PCVXVaxcyte Inc
01/02/202422:05GlobeNewswire Inc.Vaxcyte to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology ConferenceNASDAQ:PCVXVaxcyte Inc
31/01/202423:26Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:PCVXVaxcyte Inc
31/01/202405:37GlobeNewswire Inc.Vaxcyte Announces Pricing of $750 Million Public OfferingNASDAQ:PCVXVaxcyte Inc
30/01/202422:01GlobeNewswire Inc.Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded WarrantsNASDAQ:PCVXVaxcyte Inc
29/01/202414:30GlobeNewswire Inc.Vaxcyte Completes Enrollment of Phase 1/2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease (IPD) in Adults Aged 50 and OlderNASDAQ:PCVXVaxcyte Inc
16/01/202422:01GlobeNewswire Inc.Vaxcyte Appoints Whitney Jones as Chief People OfficerNASDAQ:PCVXVaxcyte Inc
04/01/202422:01GlobeNewswire Inc.Vaxcyte Provides Clinical and Regulatory Progress Update on Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV) FranchiseNASDAQ:PCVXVaxcyte Inc
05/12/202300:35GlobeNewswire Inc.VAX-24 Phase 1/2 Adult Proof-of-Concept Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 24-Valent Pneumococcal Conjugate Vaccine (PCV) CandidateNASDAQ:PCVXVaxcyte Inc
29/11/202322:46Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:PCVXVaxcyte Inc
28/11/202314:30GlobeNewswire Inc.Vaxcyte Appoints Jacks Lee to Board of DirectorsNASDAQ:PCVXVaxcyte Inc
27/11/202322:00GlobeNewswire Inc.Vaxcyte Exercises Option and Enters into Manufacturing Rights Agreement with Sutro Biopharma to Obtain Control Over Manufacturing and Development of Cell-Free Extract for its Vaccine CandidatesNASDAQ:PCVXVaxcyte Inc
09/11/202314:30GlobeNewswire Inc.Vaxcyte Doses First Participants in Phase 1/2 Clinical Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in AdultsNASDAQ:PCVXVaxcyte Inc
06/11/202322:03GlobeNewswire Inc.Vaxcyte Reports Third Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:PCVXVaxcyte Inc
31/10/202321:05GlobeNewswire Inc.Vaxcyte to Present at Upcoming Investor ConferencesNASDAQ:PCVXVaxcyte Inc
19/10/202315:29Dow Jones NewsVaxcyte Gets FDA Go-Ahead on Pneumococcal Vaccine ApplicationNASDAQ:PCVXVaxcyte Inc
19/10/202314:30GlobeNewswire Inc.Vaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-31 for the Prevention of Invasive Pneumococcal Disease in AdultsNASDAQ:PCVXVaxcyte Inc
16/10/202314:00GlobeNewswire Inc.Vaxcyte and Lonza Expand Collaboration for Global Commercial Manufacturing of Broad-Spectrum Pneumococcal Conjugate Vaccines (PCVs)NASDAQ:PCVXVaxcyte Inc
19/09/202322:05GlobeNewswire Inc.Vaxcyte to Present at the 2023 Cantor Fitzgerald Global Healthcare ConferenceNASDAQ:PCVXVaxcyte Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:PCVX
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network